A targeted regenerative framework designed to address neuropathic pain and peripheral nerve injury. This protocol integrates neurotrophic support peptides, mitochondrial stabilizers, immune modulators, and central sensitization regulators to promote nerve repair while reducing chronic neuropathic pain signaling. The objective is to interrupt pain chronification, restore neuronal integrity, and improve functional neurological recovery.
Clinical Targets
Peripheral neuropathy
Post-surgical nerve damage
Diabetic neuropathy
Complex Regional Pain Syndrome (CRPS)
Radiculopathy
Post-herpetic neuralgia
Expected Outcomes
Reduction in neuropathic pain intensity
Improved nerve conduction and sensory function
Decreased central sensitization
Enhanced mitochondrial stability within neurons
Reduced risk of pain chronification
Core Neuro-Regenerative Stack
BPC-157
Administration Route: SubQ
Dose: 500 mcg
Frequency: Twice daily
Duration: 8–12 weeks
ARA-290
Administration Route: SubQ
Dose: 2–4 mg
Frequency: Three times weekly
Duration: 8–12 weeks
SS-31
Administration Route: SubQ
Dose: 1.0 mg
Frequency: Daily
Duration: 8 weeks
Selank
Administration Route: Intranasal
Dose: 400 mcg
Frequency: Twice daily
Duration: 4–8 weeks
KPV
Administration Route: SubQ
Dose: 500 mcg
Frequency: Daily
Duration: 6–8 weeks
Phase Structure
Phase 1: Neuro-Inflammatory Control (Weeks 1–4)
BPC-157 twice daily
ARA-290 three times weekly
SS-31 daily mitochondrial support
KPV daily for inflammatory modulation
Selank twice daily to reduce central sensitization
Phase 2: Active Nerve Regeneration (Weeks 5–8)
Maintain BPC-157 and ARA-290
Continue SS-31 through Week 8
Assess sensory improvement and pain trend
Taper Selank if central symptoms stabilize
Phase 3: Remodeling & Consolidation (Weeks 9–12)
Continue BPC-157 and ARA-290 as indicated
Discontinue SS-31 after 8 weeks unless clinically necessary
Taper KPV
Reassess neurological recovery and pain thresholds
Rationale
ARA-290 serves as the centerpiece of this protocol. As an innate repair receptor (IRR) agonist derived from erythropoietin, it promotes nerve repair and reduces neuropathic pain through non-opioid pathways. BPC-157 provides neurotrophic support and has demonstrated reparative effects in preclinical nerve injury models. SS-31 stabilizes neuronal mitochondrial membranes and reduces oxidative stress, a key contributor to neuropathic pain chronification. Selank modulates GABAergic signaling and reduces central sensitization. KPV supports inflammatory regulation without broad immunosuppression.
Monitoring
Neuropathic pain scoring (VAS or neuropathic pain scale)
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.
Calculated Results
Concentration
mg/mL
( mcg/mL)
Volume mL
U-100 Units units
U-100 Insulin Syringe
0
10
20
30
40
50
60
70
80
90
100
Plunger edge aligns to exact unit mark (1 unit = 0.01 mL).
Clinical Disclaimer
This protocol is intended for informational and educational purposes for licensed healthcare professionals. These compounds and strategies are not intended to diagnose, treat, cure, or prevent any disease. Clinical evaluation and individualized medical judgment are required prior to implementation.
